Latest News

Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of MSCO.

ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies

May 14, 2026

Courtney Flaherty

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer

May 13, 2026

Ashling Wahner

Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.

Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies

May 13, 2026

Courtney Flaherty

Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.

FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML

May 13, 2026

Kristi Rosa

The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.

$FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma$

FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma

May 13, 2026

Chris Ryan

The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.

Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL

May 13, 2026

Riley Kandel

Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.

Consensus Recommendations Address Key Controversies in Lymphoma Management

May 13, 2026

Chris Ryan

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

UCSF Receives Major Gift to Advance Research and Modernization

May 13, 2026

UCSF Health

Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.

AUA and SUO Amend Advanced Prostate Cancer Guideline

May 12, 2026

Kyle Doherty

The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.

Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk

May 12, 2026

Fox Chase Cancer Center

A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.

FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma

May 12, 2026

Ashling Wahner

Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.

[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC

May 12, 2026

Kyle Doherty

[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.

FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma

May 12, 2026

Chris Ryan

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026

May 12, 2026

Kyle Doherty

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL

May 11, 2026

Riley Kandel

Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.